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Abstract: Extranasal cancers that metastasize to the sinonasal cavity are very rare. To date, there are
only limited reports regarding this rare condition within the literature. Therefore, we retrospectively
reviewed all patients diagnosed with metastatic cancer of the sinonasal tract from 2003 to 2018
at a tertiary academic medical center. Patient demographic data, clinical presentation, treatment
modalities, and outcomes were investigated. There were a total of 17 patients (9 males and 8 females)
included in the analysis. The mean age was 56.8 years (range 27–80). The most common primary
malignancies were hepatocellular carcinoma (n = 3) and gastrointestinal tract adenocarcinoma (n = 3).
The most common site of metastasis was the nasal cavity (n = 8). Five patients received radical tumor
resection and the others underwent radiotherapy, chemotherapy, or combined chemoradiotherapy.
The 2-year survival was 28%. In summary, metastasis to the sinonasal cavity remains extremely rare.
A high degree of suspicion regarding the possibility of metastatic spread to the sinonasal region
is necessary for patients with a previous history of malignancy who present with new sinonasal
symptoms. The treatment strategy of sinonasal metastatic cancer is usually palliative therapy and the
prognosis remains poor. However, early detection and diagnosis, coupled with aggressive treatment,
may improve patient quality of life.
Keywords: sinonasal malignancy; metastases; paranasal sinuses; cancer; maxillary sinus
1. Introduction
Sinonasal malignancies are extremely rare and generally present as primary malignancies. They
account for approximately 3% of upper respiratory tract malignancies [1–4]. The incidence of metastatic
tumors in the sinonasal cavity is even more unlikely [5–8]. The most common origins of metastatic
sinonasal malignancy are the kidneys, lungs, urogenital ridge, breasts, gastrointestinal tract, and
thyroid [5,9]. In the literature, renal cell carcinoma (RCC) is the most common metastatic cancer
of the sinonasal tract, accounting for almost half of all cases. Other common metastatic cancers
are bronchogenic carcinoma and urogenital ridge malignancies, such as prostate cancer and female
urogenital cancer [10,11].
Due to its limited occurrence, information regarding sinonasal metastases remains to be
investigated. In the current study, we present tumor clinicopathologic characteristics, treatment
modalities, and prognosis of 17 patients diagnosed with sinonasal metastases.
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2. Materials and Methods
2.1. Patients
This was a retrospective review of patients diagnosed with sinonasal metastases and treated at
Taipei General Veterans Hospital in Taiwan between 1 January 2003 and 31 December 2018. Institutional
Review Board approval was obtained. Data regarding patient demographics, presenting signs and
symptoms, tumor pathology, primary tumor site, metastatic sites, laboratory studies, relevant imaging
scans, treatment modalities, complications, and outcomes were collected.
2.2. Statistical analysis
Quantitative data were summarized as the mean ± standard deviation (SD) and categorical
variables as percentages. IBM SPSS 20.0 software (IBM Corp., Armonk, NY, USA) was used for the
statistic analysis. The Kaplan–Meier method was used to calculate survival trends.
3. Results
3.1. Patients
Demographic data are summarized in Table 1. There were 17 patients identified during the
study period, including 9 males and 8 females. Age at diagnosis ranged from 27 to 80 years
(mean 56.8 ± 14.2 years). In three cases, the primary and metastatic lesions were found synchronously,
and the other 14 cases experienced metastasis after the primary tumors were treated. Time from
treatment to the development of metastases ranged from 2 months to 18 years and 7 months.
Table 1. The demographic and clinical characteristics of the patients and the tumors.
Case Number (n = 17)
Age 27–80 (mean 56.8 ± 14.2)
Sex M:F = 9:8
Metastatic time 2 months–18 years and 7 months
Symptoms
Epistaxis 7
Headache 3
Nasal obstruction 2
Diplopia 1
Extraocular movement limitation 1
Facial swelling 1
Side
Unilateral (L/R) 8 (3/5)
Bilateral 7
Sinonasal metastases
Single metastases 9
Multifocal metastases 7
Widespread metastasis 11
Sinonasal metastatic sites
Nasal cavity 8
Skull base 6
Nasal septum 5
Maxillary sinus 4
Ethmoid sinus 4
Sphenoid sinus 4
Frontal sinus 1
In our study, there were eight unilateral and seven bilateral sinonasal metastases. As for metastatic
sites, eight cases metastasized to the nasal cavity, six cases to the skull base, five cases to the nasal
septum, four cases to the maxillary sinus, four cases to the ethmoid sinus, four cases to the sphenoid
sinus, and one case to the frontal sinus. Among them, nine cases manifested as a single lesion, while
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seven cases were multifocal lesions. Common symptoms included epistaxis (n = 7), headache (n = 3),
nasal obstruction (n = 2), diplopia (n = 1), extraocular movement limitation (n = 1), and facial swelling
(n = 1) (Table 1). For cases with metastatic lesions involving the nasal cavity, endoscopy often revealed
hypervascularity, friable, or polypoid lesions, which bled easily after touch (Figure 1). CT or MRI were
commonly utilized to evaluate the extent of tumor invasion (Figure 2).
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Figure 1. Endoscopic views of various sinonasal metastatic cancers. Endoscopic examinations showed
various metastatic sinonasal malignancies, which usually appeared as reddish, fragile, and hemorrhagic
masses in the nasal cavity or sinuses: (A) retroperitoneum leiomyosarcoma, (B) thyroid poorly
differentiated carcinoma, (C) breast invasive ductal carcinoma, (D) rectal adenocarcinoma, (E) hepatic
cell carcinoma, and (F) lung adenocarcinoma.
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Figure 2. CT and MRI images of sinonasal metastatic cancers: (A) A 37-year-old female diagnosed
with metastatic retroperitoneum leiomyosarcoma. The CT scan revealed that the tumor involved the
nasal chamber, bilateral sphenoid sinus, left side of the posterior ethmoid sinus, left aspect of the sellar
floor, and the clivus. (B) A 45-year-old female diagnosed with retrorectal neuroendocrine carcinoma.
The MRI scans revealed that the tumor involved the sphenoid sinus, sella, suprasella, left cavernous
sinus, and pituitary gland.
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Pathology of the primary tumors were diverse, including hepatocellular carcinoma (HCC)
(n = 3), gastrointestinal tract adenocarcinoma (n = 3), invasive ductal carcinoma of the breast
(n = 2), retroperitoneal leiomyosarcoma (n = 2), poorly differentiated thyroid carcinoma (n = 1),
thyroid papillary carcinoma (n = 1), melanoma of the foot (n = 1), osteosarcoma of the tibia (n = 1),
laryngeal mucoepidermoid carcinoma (n = 1), retrorectal neuroendocrine carcinoma (n = 1), and lung
adenocarcinoma (n = 1) (Table 2) (Figure 3). There were no cases of renal cell carcinoma.
Table 2. Primary tumor origins and pathologies.
Number (n = 17)
Primary tumor site
-GI tract 4
-Liver 3
-Breast 2
-Thyroid 2
-Retroperitoneum 1
-Broad ligament 1
-Supraglottis 1
-Lung 1
-Tibia 1
-Foot 1
Pathology
-Adenocarcinoma (GI tract) 3
-Hepatocellular carcinoma (HCC) 3
-Invasive ductal carcinoma (breast) 2
-Leiomyosarcoma (retroperitoneum, broad ligament) 2
-Poorly differentiated carcinoma (thyroid) 1
-Papillary carcinoma (thyroid) 1
-Adenocarcinoma (lung) 1
-Neuroendocrine carcinoma (retrorectum) 1
-Mucoepidermoid carcinoma (supraglottis) 1
-Osteosarcoma (tibia) 1
-Melanoma (foot) 1
J. Clin. Med. 2019, 8, 539 5 of 14
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3.2. Treatment Modality
There were five patients who underwent radical tumor excision, and one who underwent tumor
debulking. Five patients received radiotherapy, and 10 patients underwent palliative chemotherapy
(Table 3).
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Table 3. Summary of the cases of sinonasal metastatic cancer in our study.
No. Age/Sex Symptoms Primary Tumor
Clinical Stage
before Metastasis
to Sinonasal
Region
Sinonasal
Metastatic Site
Time
Before
Metastasis
Extrasinonasal
Metastasis
(Initial)
Extrasinonasal
Metastasis (Before
Sinonasal
Metastasis)
Treatment Modality Follow-upDuration
Disease
Status
1 27M HeadachePtosis Tibiaosteosarcoma Stage III (M1) NA 4y5m N Lung CT (Ifosfamide + Etoposide) NA NA
2 37F Epistaxis Retroperitoneumleiomyosarcoma Stage IV (M1)
Sphenoid,
ethmoid sinuses,
clivus
3y4m N Liver Tumor resection + RT 1m
Alive, no
obvious
residual
tumor
3 45F Headache Retrorectalneuroendocrinecarcinoma Stage IIIa (T2N1M0)
Sphenoid sinus,
pituitary gland 4m N N
Debulking surgery + CT
(cisplatin+ etoposide) 6m Dead
4 47M Epistaxis Thyroidpoorlydifferentiated carcinoma
Stage IVb
(pT3N1bM1)
Maxillary,
ethmoid,
sphenoid
sinuses, nasal
cavity, orbit,
brain
6m Left iliac Left iliac Tumor biopsy + RT + iodineablation therapy 3y11m Dead
5 48F Nasal mass Thyroid papillarycarcinoma Stage IVc (M1) Nasal septum Synchronous N N Tumor excision 2y11m
Alive, no
obvious
residual
tumor
6 49M Diplopia Gastricadenocarcinoma Stage Ib (T1N1M0) Sphenoid sinus,cavernous sinus 6y3m N N
Tumor excision + CT
(Capecitabine+ oxaliplatin+
Paclitaxel)+ Target therapy
(Cetuximab+ Uracil-Tegafur)
1y4m Dead
7 51F
EOM
limitation,
hearing
impairment
Breast invasive ductal
carcinoma Stage IV (pT3N3M1)
Ethmoid sinus,
nasal cavity,
nasal septum
11y Bone, pleural,lung Bone, pleural, lung Tumor biopsy + CT 1m22d Dead
8 53F
Facial pain,
headache,
ptosis
Rectal adenocarcinoma Stage IVb (M1) Nasal cavity,skull base, 1y1m
Lung, liver,
adrenal, bone
Lung, liver, adrenal,
bone
Tumor biopsy + CT
(Irinotecan + Fluorouracil +
Leucovorin) + Target therapy
(Bevacizumab + Cetuximab)
9m
Alive with
residual
tumor
9 56M
Epistaxis,
nasal
obstruction
Hepatocellular carcinoma StageIVb (M1)
Frontal, ethmoid
sinuses, nasal
septum, nasal
cavity, orbit
10y N Lung, brain Tumor biopsy + RT+ Targettherapy (Sorafenib) 2m Dead
10 57F Epistaxis Lungadenocarcinoma Stage IVa(cT3N2M1b) Nasal cavity Synchronous Lung, bone Lung, bone
Tumor biopsy + RT + CT
(Alimta + Cisplatin +
Docetaxel) + Target therapy
(Erlotinib + Pembrolizumab)
11m Dead
11 66F Nasal massEpistaxis
Breast invasive ductal
carcinoma
Stage IV
(pT4cN0M1) Nasal vestibule 4y3m Lung Lung
Tumor biopsy + Hormone
therapy (Tamoxifen) 2y2m
Alive with
residual
tumor
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Table 3. Cont.
No. Age/Sex Symptoms Primary Tumor
Clinical Stage
before Metastasis
to Sinonasal
Region
Sinonasal
Metastatic Site
Time
Before
Metastasis
Extrasinonasal
Metastasis
(Initial)
Extrasinonasal
Metastasis (Before
Sinonasal
Metastasis)
Treatment Modality Follow-upDuration
Disease
Status
12 66F No Broadligamentleiomyosarcoma Stage IV (M1) ITF 18y7m N
Liver, abdomen,
muscle, bone
Tumor biopsy + CT
(Gemcitabine + Taxotere +
Cisplatin + Everolimus +
Adriamycin) + Target therapy
(Pazopanib)
3m
Alive with
residual
tumor
13 67M Epistaxis Right plantar footmelanoma
Stage IIIb
(T4aN2bM0) Maxillary sinus 6 m N N
Tumor biopsy + CT
(Dacarbazine + Cisplatin +
Vinblastine + Proleukin +
Cyclophosphamide +
paclitaxel) + interferon-A +
immunotherapy (IL-2)
1y1m Dead
14 69M Nasal mass Hepatocellular carcinoma StageIVb (M1) Nasal cavity 2m Lung Lung
Tumor biopsy + CT
(Etoposide + Doxorubicin +
Cisplatin +5-FU +Leucovorin)
3d Dead
15 70M Epistaxis Cecaladenocarcinoma Stage IVc (M1) Maxilla Synchronous N N
Tumor resection + CT
(fluorouracil + oxaliplatin +
calcium folinate + irinotecan)
+ Target therapy
(bevacizumab)
3m Dead
16 77M Nasalobstruction
Supraglottic
mucoepidermoid
carcinoma
Stage IVa
(pT4N2cM0)
Maxillary sinus,
nasal cavity,
nasal septum
6m N N Tumor resection + RT 2m
Alive, no
obvious
residual
tumor
17 80M NA Hepatocellular carcinoma Stage IVb (M1) nasal septum 5y9m N Lung, muscle, bone Tumor biopsy 10m Dead
Abbreviations: F: female; M: male; EOM: extraocular movement; NA: not available; y: year; m: months; d: days; PPF: pterygoid palatine fossa; ITF: infratemporal fossa; RT: radiotherapy;
CT: chemotherapy; CCRT: concurrent chemoradiotherapy.
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3.3. Survival
The follow-up duration ranged from 1 month to 35 months. One patient was lost to follow-up
(case No. 1). At the last follow-up, three patients were free from disease (cases 2, 5, and 16), four
patients were still receiving regular follow-ups or treatment for residual and/or recurrent disease (cases
4, 8, 11, and 12), and nine patients died from disease (cases 3, 6, 7, 9, 10, 13, 14, 15, and 17) (Table 3).
The 1-year survival was 47%, and the 2-year survival was 28% (Figure 4).
 
Figure 4. The overall survival of the 17 patients with sinonasal metastases in our study.
4. Discussion
Sinonasal metastases from distant extranasal sites is exceedingly rare. In the literature, nearly half
of sinonasal metastases originated from the kidneys, followed by the lungs, breasts, colon, prostate,
urogenital ridge, gastrointestinal tract, thyroid, and pancreas (Table 4) [1,5,9,12–19]. In our study,
there were four sinonasal metastatic cases originating from the stomach and three cases from the liver,
making gastrointestinal adenocarcinoma and hepatocellular carcinoma the top two common primary
tumors. Previous cases have been largely reported in the Western literature [5,6,20–25]. However,
the incidence and distribution of malignant tumors might be diverse between different geographic
areas due to distinct genetic or environmental factors [26]. Among sinonasal metastases, the incidence
of prostate cancer and breast cancer ranked first and second highest in North America and Europe,
respectively. In North America, the incidence of kidney cancer ranked after colon cancer, melanoma,
and thyroid cancer. However, in Europe, the incidence of RCC is higher than that of melanoma. In East
Asia, the incidence of cancers of the respiratory tract have been reported to be the highest, followed by
stomach, liver, breast, and colorectal cancer; in contrast, the incidence of kidney cancer was relevantly
low [27]. According to the Taiwan Food and Drug Administration (TFDA) statistics and a study
investigating cancers between 2002 and 2012, the most common malignancy overall in Taiwan was also
breast cancer, followed by colorectal, respiratory tract, and liver cancers [28]. Huang et al. proposed
that the differences in primary cancers leading to metastatic sinonasal cancers compared to that in
Western countries might be due to a unique cancer epidemiology exclusive to Taiwan [26].
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It is well-established that chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections
are important risk factors for the development of HCC [29,30]. Incidence of HBV and HCV infection
was high in Taiwan before the launch of the HBV vaccine and other means of hepatitis virus control,
which explains the relatively higher incidence of HCC in Taiwan [13,31,32]. Therefore, HCC was
identified as one of the most common sinonasal metastases in our study, which is different from
Western studies.
Prior reports have identified the maxillary sinus as the most common site of metastasis, followed by
the sphenoid, ethmoid, frontal sinuses, and, finally, the nasal cavity [5,9,11,18,33–35]. However, in our
study, the nasal cavity was the most common site for metastasis. This is different from previous studies
and may suggest different biological behavior for distant metastatic spread based on different primaries.
The symptoms for such tumors are usually non-specific, similar to that of primary sinonasal
tumors [36], and are related to the characteristics of the primary tumor and the metastatic sites [37,38].
Due to the fact that RCC is often highly vascular [39], metastasis from RCC to the sinonasal tract is
usually accompanied by epistaxis. A tumor affecting the nasal cavity may present with epistaxis,
increased nasal secretions, and nasal obstruction. Maxillary sinus tumors may present with symptoms
of facial swelling, facial numbness, or eye symptoms. Ethmoid and sphenoid sinus tumors may result
in headache, proptosis, diplopia, or vision changes [5,20,33]. Horner’s syndrome has been reported to
result from lateral sphenoid sinus erosion or infratemporal fossa lesion [12]. If the tumor involves
the cavernous sinus or the skull base, patients may present with various cranial nerve palsies, such
as diplopia, ptosis, or visual impairment [13,35,40]. In our study, the most common symptom was
epistaxis, followed by headache and nasal obstruction. For those with frequent epistaxis and severe
nasal obstruction, surgery helps alleviate the symptoms, which might improve quality of life.
Time from treatment to the development of metastases ranged from 2 months to 18 years and
7 months. The wide variation may be related to the initial M (the presence of metastasis) stage of the
patient when diagnosed with the cancer. For cases with initial presentation of other metastatic sites,
which suggests widespread disease, the duration of the development of sinonasal metastasis should be
shorter. However, in our study, the mean metastatic duration for an initial M0 stage was 22 months
(4 cases), which was shorter compared to patients with an initial M1 stage (25 months, 8 cases), with
no significant difference between the two groups (p > 0.05). Tumor biology may play a major role in
metastatic duration, though the small sample size of this study limits more in-depth analysis.
Hematogenous [5,11,41–44] and lymphatic spread [13,37,45] are two different pathways of
metastasis. For hematogenous travel, tumor cells have to undergo intravasation, which is the process
of passing through endothelial cells into the blood vessels. Tumor cells circulate via the valveless
vertebral venous (Batson’s) plexus and can enter the pterygoid plexus and cavernous sinus, as well
as the nasal and paranasal sinuses [9,41,46,47]. As for lymphatic spread, the tumor emboli flow into
regional lymphatic channels and drain to the thoracic duct, and then flow in retrograde through
the intercostal, mediastinal, or supraclavicular lymph vessels to the head and neck region [9,13,37].
Whether tumor cells metastasize via hematogenous or lymphogenous pathways depends on multiple
factors, including the density of vascularization around the tumor or the secondary site, the biologic
behavior of the primary tumor, and the presence or absence of lymph node involvement [48].
Though rare, it is critical to keep sinonasal metastases within the differential diagnoses for
sinonasal masses. Identification of the origin of the metastatic sinonasal cancer differs from case to
case. In general, histopathologic analysis will be required to make the diagnosis. It would be prudent
to obtain imaging (CT and/or MRI) ahead of time to rule out intracranial extension, as well as to
determine the vascularity of the lesion, and also for pre-operative surgical evaluation. For extranasal
primary cancers, expression of specific biomarkers, such as carcinoembryonic antigen (CEA) and
prostate-specific antigen (PSA), may be considered. For instance, if the patient had a history of breast
cancer, the expression of human epidermal growth factor receptor 2 (HER2) and glandular morphology
in malignant cells should be checked.
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Primary sinonasal malignancies and sinonasal metastases may overlap in clinical behavior and
histopathologic appearance. Three of our cases were metastatic adenocarcinomas of gastrointestinal or
colorectal origins. This is to be distinguished from primary sinonasal intestinal-type adenocarcinoma,
which may share similar morphology and immunophenotyping, such as immunoreactivity for CK20
and cdx2. In our study, there were also two metastatic breast carcinomas, of which the morphology may
be variable and may lack specificity. Therefore, the lesion may not be easily separated from a high-grade
non-intestinal type adenocarcinoma. One of our patients was a metastatic rectal neuroendocrine
carcinoma, and its pathologic findings were identical to that of a primary sinonasal neuroendocrine
carcinoma. Therefore, the precise diagnosis of sinonasal metastases relies on the combination of clinical,
radiological, and pathologic information.
Metastases to the sinonasal cavity represent advanced distant disease and are naturally associated
with poor prognosis, and, in the vast majority of cases, may not be treated with a curative intent.
Mickel and Zimmerman reviewed the survival in 26 cases of malignancies that metastasized to the
sphenoid sinus. Only nine cases lived for more than six months and four cases survived for at least two
years [12]. Multifocal metastases in the sinonasal region have been noted to be much more common
than a single metastasis [21]. In our study, there were seven cases with multifocal metastatic tumor
in the sinonasal region, and nine cases with a single lesion. The location and number of metastatic
lesions mainly determine whether the lesion may be operable or not. Multiple metastatic lesions
and proximity to vital structures increase the challenges of surgical resection for palliation, which
would be the only possible goal in these cases [37]. In many cases, resections may be approached
endoscopically. For lesions that cannot always be excised radically, other multimodality treatments,
such as radiotherapy, chemotherapy, hormone therapy for urogenital cancer, or iodine ablation therapy
for thyroid cancer, may be considered, and should be chosen based on the characteristics of the primary
tumor. One consideration for palliative surgical candidates is preoperative embolization of feeding
vessels to reduce intraoperative bleeding [9]. Most sinonasal tumors receive blood supply from external
carotid artery branches, which would be amenable to embolization [7,9,12]. In our opinion, whether
or not patients receive surgery depends on several factors, including the general health condition of
the patient, the preferences of the surgeon, and tumor biology. We would recommend surgery if the
tumor caused frequent nasal bleeding or severe nasal obstruction (to improve quality of life), and if
the patient could tolerate general anesthesia. The location and size of the metastatic tumor should be
readily accessible. Classically, surgery is not routinely considered for metastatic disease. However,
surgery may provide some chance for these patients to live longer (decreasing tumor burden for later
chemotherapy control), and to also achieve a better quality of life (alleviating symptoms of nasal
bleeding and nasal obstruction).
In our study, 10 (58.8%) of the 17 patients died in the follow-up period. The shortest survival time
was 2 months and the longest was 35 months. There were three patients alive without obvious residual
sinonasal metastatic lesions, and three patients alive with either residual sinonasal metastases or other
distant metastases. The 1-year survival was 47%, and the 2-year survival was 28.1%. There are studies
that showed that differences in prognosis are apparent based on the presence of isolated or widespread
disseminated disease [7], with longer survival noted for an isolated sinonasal metastasis [22]. In
addition, slightly higher survival has been noted in patients that receive surgery than those who receive
radiotherapy alone [7]. However, in our study, there was no significant difference in survival whether
patients received surgery, whether the sinonasal lesions were multifocal, or whether there was isolated
or widespread disseminated disease (Supplementary Figure S1). The insignificant findings may be
related to the small number of cases, which is harder for meaningful statistical analysis.
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Table 4. Review of major case series (cases ≥ 3) of sinonasal metastatic cancers in the English language literature.
Years of
Publication Authors
Total
Patients
Age
(mean, y/o) Sex Metastatic Site Primary Tumor Sites
Follow-up
(months)
Alive with
Residual Tumor
(grossly)
Death
1959 Garrett [49] 6 58.8 5M1F 5M, 1E 1B, 1G, 1L, 1K, 2T 0.3–16 1 4
1966 Bernstein et al. [5] 10 54.2 3M7F 5M, 1E, 2F, 2N 1B, 2G, 5K, 1L, 1U 1–48 4 5
1987 Som et al. [50] 6 54 NA 3M, 2S, 1 E,1F 6K NA 0 3
1990 Mickel et al. [12] 7 49.4 5M2F 7S 3L, 1U, 2O, 1 humerus 0.25–7 NA NA
2000 Simo et al. [22] 6 67.8 3M3F NA 6K 6–48 2 4
2008 Huang et al. [26] 17 50.8 9M8F 7M, 7N, 3E, 1S, 1NP 5G, 3H, 3K, 3B, 2T, 1L NA 0 7
2008 Kaminski et al. [23] 4 61 1M3F 2M,1S,1N 1B, 2G, 1K 2–23 0 3
2011 Azarpira et al. [6] 3 58 2M1F 1E, 1M, 1S 1B, 1K, 1U 6–11 0 3
2011 Choong et al. [21] 4 55.8 3M1F 4N 4K 8–24 1 3
2012 Parida et al. [24] 3 54.3 1M2F 2F, 1N 3K 4–6 1 0
2016 Ravnik et al. [25] 3 57 1M2F 3P 1B, 1K, 1 lymphoma 8–48 2 0
2019 Chang et al.(our study) 17 56.8 9M8F
8N, 6SB, 5 septum, 4M,
4E, 4S, 1F,
2B, 4G, 3H, 1L, 2T, 1 supraglottis, 2 leg,
1 retroperitoneum, 1 broad ligament 2–228 7 9
Total 86 55.5 42M38F 27M, 11E, 16S, 4F, 23N,1 NP, 6 SB, 5 septum
10B, 14G, 6H, 7L, 31K, 6T, 3U,
1 supraglottis, 3 extremities,
1 retroperitoneum, 1 broad ligament
0.3–228 18 41
NA: not available; M: maxillary; S: sphenoid; E: ethmoid; F: frontal; N: nasal cavity; P: pituitary gland; NP: nasopharynx; SB: skull base; B: breast; G: gastrointestinal tract; H: hepatic region;
K: kidney; L: lung; T: thyroid; U: urogenital region; O: oral.
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Indeed, pathology may play a major role in patient survival. All patients with HCC and melanoma
died of the disease, which is characteristic of the known poor survival when compared to other tumor
types. One case with thyroid papillary carcinoma, a malignancy with a good prognosis, received
surgical excision of a nasal septal metastatic lesion and was still alive without obvious recurrence.
In regard to targeted therapy for metastatic breast cancer, one patient receiving target therapy was still
alive, while another who did not receive targeted therapy died of the disease. Four out of seven patients
receiving target therapy died regardless of the cancer type, including one case of HCC, one case of lung
adenocarcinoma, one case of gastric adenocarcinoma, and one case of cecal adenocarcinoma. Since this
was a retrospective study, there may be some bias to stratify the patients based on receiving targeted
therapy, due to its recent development. Cancer cases in more recent years would be more likely to
receive the novel targeted therapies compared to those from prior years. In our study, 11 patients had
widespread metastatic disease when sinonasal metastasis (e.g., lung, bone, liver, brain) was diagnosed,
while 5 cases presented with isolated sinonasal metastasis.
In our study, gastrointestinal adenocarcinoma and hepatocellular carcinoma were the top two
common primary tumors that metastasized to the sinonasal tract, which is quite different from reports
on Western countries. The nasal cavity was the most common site for metastasis, which is also quite
different from previous reports where the maxillary sinus was the most common site. The similar
findings included the mean age, the sex distribution, and the poor prognosis (Table 4). There are
several limitations to our study. First, it is a retrospective study, which makes complete data collection
and verification difficult. Second, the small number of cases for such a rare condition, may prevent
meaningful statistical analysis. Finally, treatment plans for each patient may be impacted by physician
and/or patient preference, where electing to be more aggressive with treatment may affect survival.
5. Conclusions
Sinonasal metastases from extranasal primary malignancies are rare, and patients usually suffer
from non-specific symptoms. Treatment modalities differ based on the origin and characteristics of the
primary tumor. The prognosis remains poor, though early detection and aggressive treatment may
help to improve quality of life.
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